The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| AMRX | +28.65% | +187.44% | +23.51% | -20% |
| S&P | +14.49% | +91.09% | +13.83% | +156% |
Amneal Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development, manufacture, market and distribution of generic pharmaceutical products. It operates through the Generic, Specialty and AvKARE Segments. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermals. The Specialty segment provides proprietary medicines to the U.S. market. The AvKARE segment focuses on pharmaceuticals, medical and surgical products, and services primarily to governmental agencies. The company was founded by Chintu Patel and Chirag Patel in 2002 and is headquartered in Bridgewater, NJ.
The company received a complete response letter from the FDA regarding a Parkinson's disease generic therapy.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $784.51M | 11.7% |
| Gross Profit | $273.97M | 1.6% |
| Gross Margin | 34.92% | -3.5% |
| Market Cap | $3.14B | 22.1% |
| Market Cap / Employee | $0.38M | 0.0% |
| Employees | 8.3K | 5.7% |
| Net Income | $18.13M | 54.2% |
| EBITDA | $126.88M | -14.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $235.98M | 201.2% |
| Accounts Receivable | $885.20M | 18.3% |
| Inventory | 614.5 | 3.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $2.66B | 17.7% |
| Short Term Debt | $21.47M | -94.4% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 0.17% | 5.3% |
| Return On Invested Capital | -1.97% | 1.4% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $103.40M | -17.1% |
| Operating Free Cash Flow | $118.45M | -16.5% |
| Metric | Q2 2025 | Q3 2025 | YoY Change | ||
|---|---|---|---|---|---|
| Price to Earnings | 1264.06 | 704.93 | - | ||
| Price to Book | -26.26 | -23.77 | -19.26 | -28.04 | 1.65% |
| Price to Sales | 0.88 | 0.96 | 0.91 | 1.11 | 15.24% |
| Price to Tangible Book Value | -1.67 | -1.80 | -1.79 | -2.31 | 32.10% |
| Price to Free Cash Flow TTM | 10.46 | 11.20 | 9.63 | 13.03 | -48.78% |
| Enterprise Value to EBITDA | 34.19 | 33.61 | 29.71 | 45.46 | 29.96% |
| Free Cash Flow Yield | 9.6% | 8.9% | 10.4% | 7.7% | 95.22% |
| Return on Equity | -52.8% | -146.3% | -134.0% | -155.4% | - |
| Total Debt | $2.59B | $2.58B | $2.58B | $2.69B | 1.55% |
No podcast episodes available.
AMRX earnings call for the period ending September 30, 2021.
AMRX earnings call for the period ending June 30, 2021.
AMRX earnings call for the period ending March 31, 2021.
AMRX earnings call for the period ending December 31, 2020.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
